Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600305 | 1.00 | PPARG (0.39) | PPARGPPARAACACBCTSLCTSK | |
| SCHEMBL4600010 | 0.89 | LDHA (0.47) | PPARGPPARALDHAKMT2A | |
| SCHEMBL30510242 | 0.89 | LDHA (0.47) | PPARGPPARALDHAKMT2A | |
| SCHEMBL4600752 | 0.88 | CTRB1 (0.40) | PPARGPPARAITGB1ITGA4CTRB1 | |
| SCHEMBL30510366 | 0.88 | CTRB1 (0.40) | PPARGPPARAITGB1ITGA4CTRB1 | |
| SCHEMBL4600067 | 0.88 | CTRB1 (0.40) | PPARGPPARAITGB1ITGA4CTRB1 | |
| SCHEMBL5407004 | 0.88 | CTRB1 (0.40) | PPARGPPARAITGB1ITGA4CTRB1 | |
| SCHEMBL25177964 | 0.86 | ATM (0.39) | PPARGPPARAITGB1ITGA4KMT2A | |
| SCHEMBL30767800 | 0.86 | ATM (0.39) | PPARGPPARAITGB1ITGA4KMT2A | |
| SCHEMBL5403825 | 0.86 | ITGA4 (0.42) | PPARGPPARAITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275105-B1 | Heterocyclic derivatives as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-05 | — | — | EP | disclosed |
| EP-1499313-B1 | HETEROCYCLIC DERIVATIVES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-29 | — | — | EP | disclosed |
| EP-2275105-A1 | Heterocyclic derivatives as opioid receptor modulators | Janssen Pharmaceutica NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-7659402-B2 | use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7202381-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7041681-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-09 | — | — | US | disclosed |
| US-20060030558-A1 | Novel compounds as opioid receptor modulators | BRESLIN HENRY J | 2006-02-09 | — | — | US | disclosed |
| US-20050187252-A1 | 2-Amino-3-(4-hydroxy-phenyl)-1-[2-(5-phenyl-oxazol-2-yl)-piperidin-1-yl]-propan-1-one; pain and gastrointestinal disorders | BRESLIN HENRY J (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1499313-A2 | HETEROCYCLIC DERIVATIVES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-26 | — | — | EP | disclosed |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003092688-A2 | HETEROCYCLIC DERIVATIVES AS OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030558-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | PPARG 870/4885PPARA 1006/4885ACACB 4538/4885 |
| US-20050187252-A1 | 2-Amino-3-(4-hydroxy-phenyl)-1-[2-(5-phenyl-oxazol-2-yl)-piperidin-1-yl]-propan-1-one; pain and gastrointestinal disorders | OPRL1, OPRK1, OPRD1 | PPARG 609/4885PPARA 453/4885ACACB 3946/4885 |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | PPARG 870/4885PPARA 1006/4885ACACB 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.